GlassScriptPhysician profile
Juan C Roman
NPI 1851510036
$8,424.28
in general payments reported to CMS, 2019-2025
14 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,273 · 2020: $2,264 · 2021: $1,213 · 2022: $2,561 · 2023: $402 · 2024: $422 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.18 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,239.50 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Merck Sharp & Dohme LLC | $2,009.06 | 2019-2024 | Janumet, Verquvo, Januvia |
| E.R. Squibb & Sons, L.L.C. | $1,325.00 | 2020-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $634.73 | 2019-2023 | |
| Novo Nordisk INC | $557.55 | 2019-2023 | Rybelsus, Ozempic |
| Pbg Puerto Rico LLC | $537.87 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $331.41 | 2019-2024 | Xarelto, Invokana |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.74 | 2019-2025 | Jardiance |
| Eli Lilly Export S.A. Puerto Rico Branch | $207.10 | 2020-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $93.46 | 2025 | Austedo Xr |
| Lilly USA, LLC | $90.91 | 2019 | |
| Mylan LLC | $26.05 | 2020 | |
| Exact Sciences Corporation | $25.00 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $23.90 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.